Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452186 | 0.92 | FGFR1 (0.37) | FGFR1L3MBTL1POLA1KDM4EALDH1A1 | |
| SCHEMBL891699 | 0.91 | L3MBTL1 (0.38) | FGFR1L3MBTL1POLA1ALDH1A1 | |
| SCHEMBL891868 | 0.86 | LMNA (0.36) | L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL891584 | 0.79 | LMNA (0.36) | L3MBTL1ALDH1A1POLB | |
| SCHEMBL13161000 | 0.77 | PDE4D (0.51) | FGFR1L3MBTL1POLA1POLB | |
| SCHEMBL891938 | 0.72 | LMNA (0.36) | L3MBTL1ALDH1A1POLB | |
| SCHEMBL2497500 | 0.72 | L3MBTL1 (0.65) | L3MBTL1 | |
| SCHEMBL13160996 | 0.71 | POLA1 (0.62) | FGFR1L3MBTL1POLA1POLB | |
| SCHEMBL891962 | 0.71 | LMNA (0.38) | L3MBTL1ALDH1A1 | |
| SCHEMBL13160997 | 0.70 | PDE3A (0.59) | FGFR1L3MBTL1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | claimed |
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MTAP, NSUN2, CDA | FGFR1 4371/4885L3MBTL1 1279/4885POLA1 1477/4885 |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | MTAP, NSUN2, PAICS | FGFR1 4431/4885L3MBTL1 1504/4885POLA1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.